Abstract:Microglia are macrophage-like resident immune cells that contribute to the maintenance of homeostasis in the central nervous system (CNS). Abnormal activation of microglia can cause damage in the CNS, and accumulation of activated microglia is a characteristic pathological observation in neurologic conditions such as trauma, stroke, inflammation, epilepsy, and neurodegenerative diseases. Activated microglia secrete high levels of glutamate, which damages CNS cells and has been implicated as a major cause of neurodegeneration in these conditions. Glutamate-receptor blockers and microglia inhibitors (e.g., minocycline) have been examined as therapeutic candidates for several neurodegenerative diseases; however, these compounds exerted little therapeutic benefit because they either perturbed physiological glutamate signals or suppressed the actions of protective microglia. The ideal therapeutic approach would hamper the deleterious roles of activated microglia without diminishing their protective effects. We recently found that abnormally activated microglia secrete glutamate via gap-junction hemichannels on the cell surface. Moreover, administration of gap-junction inhibitors significantly suppressed excessive microglial glutamate release and improved disease symptoms in animal models of neurologic conditions such as stroke, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Recent evidence also suggests that neuronal and glial communication via gap junctions amplifies neuroinflammation and neurodegeneration. Elucidation of the precise pathologic roles of gap junctions and hemichannels may lead to a novel therapeutic strategies that can slow and halt the progression of neurodegenerative diseases.

Connexin:a Potential Novel Target for Protecting the Central Nervous System?

Connexin Hemichannels in Astrocytes: Role in CNS Disorders

[Gap Junction and Function of Brain].

Function of Connexins in the Interaction between Glial and Vascular Cells in the Central Nervous System and Related Neurological Diseases

Stem Cells in Central Nervous System Diseases: Promising Therapeutic Strategies.

Connexins as therapeutic targets in neurological and neuropsychiatric disorders

Role of Connexins 30, 36, and 43 in Brain Tumors, Neurodegenerative Diseases, and Neuroprotection

Gap junctions and hemichannels composed of connexins: potential therapeutic targets for neurodegenerative diseases

Astroglial Connexins In Neurodegenerative Diseases

Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection

Role of connexins in neurodegenerative diseases (Review)

CNS and CNS Diseases in Relation to Their Immune System

Piezo1: the Key Regulators in Central Nervous System Diseases

The Role of Gap Junction Channels During Physiologic and Pathologic Conditions of the Human Central Nervous System

Modulation of brain hemichannels and gap junction channels by pro-inflammatory agents and their possible role in neurodegeneration

Pathological function of transient receptor potential canonical 6 channel in key central nervous system diseases:its prospects as drug targets

Connexin 43 Phosphorylation: Implications in Multiple Diseases

Meningeal Immunity and Neurological Diseases: New Approaches, New Insights

Expression of Connexin 36 in Central Nervous System and Its Role in Epileptic Seizure.

Purification, Reconstitution, and Functional Analysis of Connexin Hemichannels

Connexin 43, a new therapeutic target for cardiovascular diseases